Why lithium studies for ALS treatment should not be halted prematurely by Galila Agam & Adrian Israelson
GENERAL COMMENTARY
published: 02 September 2014
doi: 10.3389/fnins.2014.00267
Why lithium studies for ALS treatment should not be
halted prematurely
Galila Agam1* and Adrian Israelson2*
1 Department of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences and Psychiatry Research Unit, Ben Gurion University of the Negev, Beer
Sheva, Israel
2 Department of Physiology and Cell Biology, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel
*Correspondence: galila@bgu.ac.il; adriani@bgu.ac.il
Edited by:
John A. Rudd, Chinese University of Hong-Kong, China
Reviewed by:
Stina Syvänen, Uppsala University, Sweden
Keywords: lithium, ALS, effective blood levels, riluzole, mouse strains
A commentary on
Make mouse studies work
by Perrin, S. (2014). Nature 507, 423–425.
doi: 10.1038/507423a
Perrin’s recent comment (Perrin, 2014)
emphasizes that mouse studies must be
sibling-matched, gender-balanced, and
investigator-blinded. To substantiate his
claim, Perrin provides examples from
studies on lithium as a treatment for ALS,
describing them as misleading. While
we fully agree that there is a need for
better designed preclinical studies and
better characterization of disease mod-
els, Perrin’s examples are problematic.
First, Perrin’s pharmacokinetic calcu-
lations of the dosing regimens predict
plasma lithium levels of 0.3–1.68meq/L.
However, given that the beneficial ther-
apeutic window in bipolar-disorder is
0.6–1.5meq lithium/L, it is conceivable
that only regimens resulting in blood
levels ≥0.6meq/L would lead to benefi-
cial results. Second, instead of theoretical
calculations lithium levels should be mea-
sured directly. We recently reported that
lithium blood levels of ICR mice bred sep-
arately in the USA and Israel, but treated
in the same facility with the same supple-
mented food, differed by 2.5-fold (Sade
et al., 2014). This difference may explain
why, despite using the same regime, the
Fornai et al. (2008) and Gill et al. (2009)
studies produced opposite results. Third,
daily intraperitoneal lithium injections
rather than the less irritating food supple-
mentation method might also contribute
to unsuccessful outcomes.
In negative ALS clinical trials
(UKMND-LiCALS Study Group et al.,
2013) plasma lithium levels were
0.4–0.8meq/L, barely at the lower
therapeutic range for psychiatric disor-
ders and significantly lower than the Ki for
lithium of its major hypothesized targets
(≥1mM). Indeed, in the antidepressant-
like rodent model, the forced-swim test,
only plasma lithium levels above 1.3meq/L
significantly reduced immobility-time
(Bersudsky et al., 2007). Importantly, it has
recently been shown (Yáñez et al., 2014)
that lithium-induced neuroprotection is
antagonized by riluzole (the only FDA-
approved drug for ALS), suggesting that
the drug’s neurotoxic effects may mask
the potential neuroprotective activity of
lithium.
In conclusion, we believe that the
potential beneficial effect of lithium for
neurodegenerative disorders deserves seri-
ous reconsideration.
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